{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:57:00Z","timestamp":1790848620713,"version":"4.1.0"},"reference-count":171,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"OSU College of Medicine Research Scholarship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Glioblastoma (GBM) is an aggressive primary brain tumor that is associated with a poor prognosis and quality of life. The standard of care has changed minimally over the past two decades and currently consists of surgery followed by radiotherapy (RT), concomitant and adjuvant temozolomide, and tumor treating fields (TTF). Factors such as tumor hypoxia and the presence of glioma stem cells contribute to the radioresistant nature of GBM. In this review, we discuss the current treatment modalities, mechanisms of radioresistance, and studies that have evaluated promising radiosensitizers. Specifically, we highlight small molecules and immunotherapy agents that have been studied in conjunction with RT in clinical trials. Recent preclinical studies involving GBM radiosensitizers are also discussed.<\/jats:p>","DOI":"10.3390\/biomedicines10071763","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T10:36:56Z","timestamp":1658399816000},"page":"1763","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0693-0404","authenticated-orcid":false,"given":"Jennifer K.","family":"Matsui","sequence":"first","affiliation":[{"name":"College of Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8667-0782","authenticated-orcid":false,"given":"Haley K.","family":"Perlow","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Ritter","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituraj","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju R.","family":"Raval","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan M.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha J.","family":"Beyer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Pillainayagam","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Goranovich","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Ong","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Giglio","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-0129","authenticated-orcid":false,"given":"Joshua D.","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nou223","article-title":"CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007\u20132011","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ali, M.Y., Oliva, C.R., Noman, A.S.M., Allen, B.G., Goswami, P.C., Zakharia, Y., Monga, V., Spitz, D.R., Buatti, J.M., and Griguer, C.E. (2020). Radioresistance in Glioblastoma and the Development of Radiosensitizers. Cancers, 12.","DOI":"10.3390\/cancers12092511"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3171\/2011.2.JNS10998","article-title":"An Extent of Resection Threshold for Newly Diagnosed Glioblastomas: Clinical Article","volume":"115","author":"Sanai","year":"2011","journal-title":"J. Neurosurg. JNS"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3171\/2015.5.JNS142087","article-title":"The Influence of Maximum Safe Resection of Glioblastoma on Survival in 1229 Patients: Can We Do Better than Gross-Total Resection?","volume":"124","author":"Li","year":"2016","journal-title":"J. Neurosurg. JNS"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00701-015-2621-3","article-title":"Long-Term Outcomes after Supratotal Resection of Diffuse Low-Grade Gliomas: A Consecutive Series with 11-Year Follow-Up","volume":"158","author":"Duffau","year":"2016","journal-title":"Acta Neurochir."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Oronsky, B., Reid, T.R., Oronsky, A., Sandhu, N., and Knox, S.J. (2021). A Review of Newly Diagnosed Glioblastoma. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.574012"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","article-title":"Emerging Therapies for Glioblastoma: Current State and Future Directions","volume":"41","author":"Rong","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e876","DOI":"10.1038\/cddis.2013.388","article-title":"O6-Methylguanine DNA Methyltransferase as a Promising Target for the Treatment of Temozolomide-Resistant Gliomas","volume":"4","author":"Fan","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_11","first-page":"1957","article-title":"P53 Effects Both the Duration of G2\/M Arrest and the Fate of Temozolomide-Treated Human Glioblastoma Cells","volume":"61","author":"Hirose","year":"2001","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0167-8140(02)00078-6","article-title":"Radiotherapy for Newly Diagnosed Malignant Glioma in Adults: A Systematic Review","volume":"64","author":"Laperriere","year":"2002","journal-title":"Radiother. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/nyas.12112","article-title":"Tumor Treating Fields: A New Frontier in Cancer Therapy","volume":"1291","author":"Davies","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs. Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13014-020-01584-6","article-title":"Survival after Hypofractionation in Glioblastoma: A Systematic Review and Meta-Analysis","volume":"15","author":"Trone","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3389\/fonc.2019.01017","article-title":"Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis","volume":"9","author":"Liao","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11060-021-03925-1","article-title":"Dose-Escalated Accelerated Hypofractionation for Elderly or Frail Patients with a Newly Diagnosed Glioblastoma","volume":"156","author":"Perlow","year":"2022","journal-title":"J. Neurooncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/cncr.34192","article-title":"Accelerated Hypofractionated Radiation for Elderly or Frail Patients with a Newly Diagnosed Glioblastoma: A Pooled Analysis of Patient-Level Data from 4 Prospective Trials","volume":"128","author":"Perlow","year":"2022","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0360-3016(99)00336-3","article-title":"Single Dose versus Fractionated Stereotactic Radiotherapy for Recurrent High-Grade Gliomas","volume":"45","author":"Cho","year":"1999","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8863","DOI":"10.1200\/JCO.2005.03.4157","article-title":"Efficacy of Fractionated Stereotactic Reirradiation in Recurrent Gliomas: Long-Term Results in 172 Patients Treated in a Single Institution","volume":"23","author":"Combs","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","article-title":"Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade Gliomas","volume":"28","author":"Fogh","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijrobp.2008.02.003","article-title":"High-Dose Single-Fraction Radiotherapy: Exploiting a New Biology?","volume":"71","author":"Brown","year":"2008","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using Immunotherapy to Boost the Abscopal Effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tharmalingam, H., and Hoskin, P.J. (2017). The Optimism Surrounding Stereotactic Body Radiation Therapy and Immunomodulation. Chin. Clin. Oncol., 6.","DOI":"10.21037\/cco.2017.05.01"},{"key":"ref_26","first-page":"8105","article-title":"Comparative Analysis of Necrotic and Apoptotic Tumor Cells As a Source of Antigen(s) in Dendritic Cell-Based Immunization","volume":"61","author":"Kotera","year":"2001","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2018.36.15_suppl.2046","article-title":"Hypofractionnated Stereotactic Radiotherapy and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: Results of the Phase I Part of the Phase I\/II STERIMGLI Trial","volume":"36","author":"Pouessel","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fonc.2013.00284","article-title":"Potential Applications of Imaging and Image-Guided Radiotherapy for Brain Metastases and Glioblastoma to Improve Patient Quality of Life","volume":"3","author":"Nguyen","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.prro.2014.03.012","article-title":"Long-Term Survival after Treatment of Glioblastoma Multiforme with Hyperfractionated Concomitant Boost Proton Beam Therapy","volume":"5","author":"Mizumoto","year":"2015","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3171\/jns.1999.91.2.0251","article-title":"Accelerated Fractionated Proton\/Photon Irradiation to 90 Cobalt Gray Equivalent for Glioblastoma Multiforme: Results of a Phase II Prospective Trial","volume":"91","author":"Fitzek","year":"1999","journal-title":"J. Neurosurg."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Combs, S.E., Kieser, M., Rieken, S., Habermehl, D., J\u00e4kel, O., Haberer, T., Nikoghosyan, A., Haselmann, R., Unterberg, A., and Wick, W. (2010). Randomized Phase II Study Evaluating a Carbon Ion Boost Applied after Combined Radiochemotherapy with Temozolomide versus a Proton Boost after Radiochemotherapy with Temozolomide in Patients with Primary Glioblastoma: The CLEOPATRA Trial. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-478"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ch\u00e9deville, A.L., and Madureira, P.A. (2021). The Role of Hypoxia in Glioblastoma Radiotherapy Resistance. Cancers, 13.","DOI":"10.3390\/cancers13030542"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.molcel.2004.10.029","article-title":"A Pathway of Double-Strand Break Rejoining Dependent upon ATM, Artemis, and Proteins Locating to \u03b3-H2AX Foci","volume":"16","author":"Riballo","year":"2004","journal-title":"Mol. Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/09553007814550011","article-title":"Gamma-Ray Induced Double-Strand Breaks in DNA Resulting from Randomly-Inflicted Single-Strand Breaks: Temporal Local Denaturation, a New Radiation Phenomenon?","volume":"33","year":"1978","journal-title":"Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Nickoloff, J.A., Sharma, N., and Taylor, L. (2020). Clustered DNA Double-Strand Breaks: Biological Effects and Relevance to Cancer Radiotherapy. Genes, 11.","DOI":"10.3390\/genes11010099"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.dnarep.2008.05.007","article-title":"Chromium-Mediated Apoptosis: Involvement of DNA-Dependent Protein Kinase (DNA-PK) and Differential Induction of P53 Target Genes","volume":"7","author":"Hill","year":"2008","journal-title":"DNA Repair"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.mrrev.2010.01.014","article-title":"Plasma Membrane Signaling Induced by Ionizing Radiation","volume":"704","author":"Corre","year":"2010","journal-title":"Mutat. Res. \/Rev. Mutat. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41422-019-0263-3","article-title":"The Role of Ferroptosis in Ionizing Radiation-Induced Cell Death and Tumor Suppression","volume":"30","author":"Lei","year":"2020","journal-title":"Cell Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Carlos-Reyes, A., Mu\u00f1iz-Lino, M.A., Romero-Garcia, S., L\u00f3pez-Camarillo, C., and Hern\u00e1ndez-de la Cruz, O.N. (2021). Biological Adaptations of Tumor Cells to Radiation Therapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.718636"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrc2499","article-title":"Cancer Stem Cells in Solid Tumours: Accumulating Evidence and Unresolved Questions","volume":"8","author":"Visvader","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma Stem Cells Promote Radioresistance by Preferential Activation of the DNA Damage Response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A Restricted Cell Population Propagates Glioblastoma Growth after Chemotherapy","volume":"488","author":"Chen","year":"2012","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Fidoamore, A., Cristiano, L., Antonosante, A., d\u2019Angelo, M., Di Giacomo, E., Astarita, C., Giordano, A., Ippoliti, R., Benedetti, E., and Cimini, A. (2016). Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance. Stem Cells Int., 2016.","DOI":"10.1155\/2016\/6809105"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An Integrated Genomic Analysis of Human Glioblastoma Multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/bjc.1955.55","article-title":"The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy","volume":"9","author":"Thomlinson","year":"1955","journal-title":"Br. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1259\/0007-1285-26-312-638","article-title":"The Concentration of Oxygen Dissolved in Tissues at the Time of Irradiation as a Factor in Radiotherapy","volume":"26","author":"Gray","year":"1953","journal-title":"Br. J. Radiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00000421-199808000-00008","article-title":"The Oxygen Fixation Hypothesis: A Reevaluation","volume":"21","author":"Ewing","year":"1998","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Farace, C., Oliver, J.A., Melguizo, C., Alvarez, P., Bandiera, P., Rama, A.R., Malaguarnera, G., Ortiz, R., Madeddu, R., and Prados, J. (2015). Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells. PLOS ONE, 10.","DOI":"10.1371\/journal.pone.0134111"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Dapash, M., Hou, D., Castro, B., Lee-Chang, C., and Lesniak, M.S. (2021). The Interplay between Glioblastoma and Its Microenvironment. Cells, 10.","DOI":"10.3390\/cells10092257"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Da Ros, M., De Gregorio, V., Iorio, A.L., Giunti, L., Guidi, M., De Martino, M., Genitori, L., and Sardi, I. (2018). Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19102879"},{"key":"ref_51","first-page":"6449","article-title":"Blood Flow, Oxygen and Nutrient Supply, and Metabolic Microenvironment of Human Tumors: A Review","volume":"49","author":"Vaupel","year":"1989","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0360-3016(79)90044-0","article-title":"Exploitable Mechanisms in Combined Radiotherapy-Chemotherapy: The Concept of Additivity","volume":"5","author":"Peckham","year":"1979","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1039\/C8CS00641E","article-title":"Transition Metal Compounds as Cancer Radiosensitizers","volume":"48","author":"Gill","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0305-7372(76)80012-6","article-title":"Radiosensitizers of Hypoxic Cells in Solid Tumours","volume":"3","author":"Fowler","year":"1976","journal-title":"Cancer Treat. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/oxfordjournals.bmb.a070956","article-title":"Chemical radiosensitization of hypoxic cells","volume":"29","author":"Adams","year":"1973","journal-title":"Br. Med. Bull."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.drudis.2017.10.010","article-title":"Gemcitabine and Glioblastoma: Challenges and Current Perspectives","volume":"23","author":"Bastiancich","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/ncponc1155","article-title":"Mechanisms of Disease: Temozolomide and Glioblastoma\u2014Look to the Future","volume":"5","author":"Mrugala","year":"2008","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1158\/1078-0432.CCR-06-0596","article-title":"Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms","volume":"12","author":"Chakravarti","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0305-7372(93)90026-N","article-title":"Clinical and Preclinical Activity of 2\u2032,2\u2032- Difluorodeoxycytidine (Gemcitabine)","volume":"19","author":"Lund","year":"1993","journal-title":"Cancer Treat. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/srao.2003.50002","article-title":"The Mechanism of Action of Radiosensitization of Conventional Chemotherapeutic Agents","volume":"13","author":"Lawrence","year":"2003","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0360-3016(03)01443-3","article-title":"Cell Cycle Effect of Gemcitabine and Its Role in the Radiosensitizing Mechanism in Vitro","volume":"57","author":"Pauwels","year":"2003","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0360-3016(98)00105-9","article-title":"Radiosensitizing Potential of Gemcitabine (2\u2032,2\u2032-Difluoro-2\u2032-Deoxycytidine) within the Cell Cycle in Vitro","volume":"41","author":"Latz","year":"1998","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and Pharmacogenetics of Gemcitabine as a Mainstay in Adult and Pediatric Oncology: An EORTC-PAMM Perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_64","first-page":"24","article-title":"Gemcitabine-Mediated Radiosensitization","volume":"24","author":"Lawrence","year":"1997","journal-title":"Semin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.bjc.6602444","article-title":"Gemcitabine Twice Weekly as a Radiosensitiser for the Treatment of Brain Metastases in Patients with Carcinoma: A Phase I Study","volume":"92","author":"Maraveyas","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-007-9489-x","article-title":"Fixed Dose-Rate Gemcitabine as Radiosensitizer for Newly Diagnosed Glioblastoma: A Dose-Finding Study","volume":"87","author":"Fabi","year":"2008","journal-title":"J. Neurooncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00280-009-1155-x","article-title":"Phase II Study of Fixed Dose Rate Gemcitabine as Radiosensitizer for Newly Diagnosed Glioblastoma Multiforme","volume":"65","author":"Metro","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/annonc\/mdn543","article-title":"Gemcitabine Uptake in Glioblastoma Multiforme: Potential as a Radiosensitizer","volume":"20","author":"Sigmond","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3171\/jns.2003.99.5.0893","article-title":"Safety and Efficacy of Convection-Enhanced Delivery of Gemcitabine or Carboplatin in a Malignant Glioma Model in Rats","volume":"99","author":"Degen","year":"2003","journal-title":"J. Neurosurg."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s002800100284","article-title":"Targeted Delivery of a Peripheral Benzodiazepine Receptor Ligand-Gemcitabine Conjugate to Brain Tumors in a Xenograft Model","volume":"48","author":"Guo","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.brainres.2009.01.011","article-title":"Antitumor Effects of Polysorbate-80 Coated Gemcitabine Polybutylcyanoacrylate Nanoparticles in Vitro and Its Pharmacodynamics in Vivo on C6 Glioma Cells of a Brain Tumor Model","volume":"1261","author":"Wang","year":"2009","journal-title":"Brain Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12272-020-01232-3","article-title":"Small Molecule Tyrosine Kinase Inhibitors in Glioblastoma","volume":"43","author":"Kim","year":"2020","journal-title":"Arch. Pharm. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/313144a0","article-title":"Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin","volume":"313","author":"Libermann","year":"1985","journal-title":"Nature"},{"key":"ref_74","first-page":"4307","article-title":"The Epidermal Growth Factor Receptor Pathway Mediates Resistance to Sequential Administration of Radiation and Chemotherapy in Primary Human Glioblastoma Cells in a RAS-Dependent Manner","volume":"62","author":"Chakravarti","year":"2002","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0360-3016(01)01609-1","article-title":"EGFR Overexpression and Radiation Response in Glioblastoma Multiforme","volume":"51","author":"Barker","year":"2001","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1215\/S1522851705000451","article-title":"Phase 1 Study of Erlotinib HCl Alone and Combined with Temozolomide in Patients with Stable or Recurrent Malignant Glioma","volume":"8","author":"Prados","year":"2006","journal-title":"Neuro-Oncology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/17476348.2.2.167","article-title":"Erlotinib: An EGF Receptor Tyrosine Kinase Inhibitor in Non-Small-Cell Lung Cancer Treatment","volume":"2","author":"Schettino","year":"2008","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1200\/JCO.2008.18.0612","article-title":"Phase I\/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177","volume":"26","author":"Brown","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-009-0067-2","article-title":"Phase II Trial of Erlotinib with Temozolomide and Radiation in Patients with Newly Diagnosed Glioblastoma Multiforme","volume":"98","author":"Peereboom","year":"2010","journal-title":"J. Neurooncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ijrobp.2010.01.070","article-title":"Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo\/North Central Cancer Treatment Group Study N0074","volume":"80","author":"Uhm","year":"2011","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_81","first-page":"430","article-title":"Phase I\/Randomized Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, with or without Protracted Temozolomide in Adults with Recurrent Glioblastoma","volume":"17","author":"Reardon","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Brown, N., McBain, C., Nash, S., Hopkins, K., Sanghera, P., Saran, F., Phillips, M., Dungey, F., Clifton-Hadley, L., and Wanek, K. (2016). Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent\/Progressive Glioblastoma. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156369"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13046-019-1235-7","article-title":"The Third-Generation EGFR Inhibitor AZD9291 Overcomes Primary Resistance by Continuously Blocking ERK Signaling in Glioblastoma","volume":"38","author":"Liu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_84","first-page":"22","article-title":"PI3K\/Akt\/MTOR Signaling Pathway and Targeted Therapy for Glioblastoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"MTOR Signaling in Growth Control and Disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jbior.2014.09.004","article-title":"Distinct Signaling Mechanisms of MTORC1 and MTORC2 in Glioblastoma Multiforme: A Tale of Two Complexes","volume":"57","author":"Gillick","year":"2015","journal-title":"Adv. Biol. Regul."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jbior.2019.03.003","article-title":"Diverse Signaling Mechanisms of MTOR Complexes: MTORC1 and MTORC2 in Forming a Formidable Relationship","volume":"72","author":"Wainwright","year":"2019","journal-title":"Adv. Biol. Regul."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Dumas, A.A., Pomella, N., Rosser, G., Guglielmi, L., Vinel, C., Millner, T.O., Rees, J., Aley, N., Sheer, D., and Wei, J. (2020). Microglia Promote Glioblastoma via MTOR-Mediated Immunosuppression of the Tumour Microenvironment. EMBO J., 39.","DOI":"10.15252\/embj.2019103790"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-15-3153","article-title":"Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)","volume":"22","author":"Wick","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11060-009-9950-0","article-title":"Phase 2 Trial of Erlotinib plus Sirolimus in Adults with Recurrent Glioblastoma","volume":"96","author":"Reardon","year":"2010","journal-title":"J. Neurooncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1593\/neo.05361","article-title":"Disruption of Parallel and Converging Signaling Pathways Contributes to the Synergistic Antitumor Effects of Simultaneous MTOR and EGFR Inhibition in GBM Cells","volume":"7","author":"Rao","year":"2005","journal-title":"Neoplasia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/neuonc\/nou328","article-title":"A Phase II Trial of Everolimus, Temozolomide, and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: NCCTG N057K","volume":"17","author":"Ma","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/neuonc\/nox209","article-title":"A Randomized Phase II Study of Everolimus in Combination with Chemoradiation in Newly Diagnosed Glioblastoma: Results of NRG Oncology RTOG 0913","volume":"20","author":"Chinnaiyan","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"MTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt","volume":"66","author":"Rojo","year":"2006","journal-title":"Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/neuonc\/not139","article-title":"The MTORC1\/MTORC2 Inhibitor AZD2014 Enhances the Radiosensitivity of Glioblastoma Stem-like Cells","volume":"16","author":"Kahn","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tips.2017.11.003","article-title":"Cancer Radiosensitizers","volume":"39","author":"Wang","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/09553007114550751","article-title":"Electron Affinic Sensitization","volume":"19","author":"Adams","year":"1971","journal-title":"Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"De, P., and Roy, K. (2022). Nitroaromatics as Hypoxic Cell Radiosensitizers: A 2D-QSAR Approach to Explore Structural Features Contributing to Radiosensitization Effectiveness. Eur. J. Med. Chem. Rep., 4.","DOI":"10.1016\/j.ejmcr.2022.100035"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/0360-3016(89)90917-6","article-title":"Misonidazole Combined with Split-Course Radiotherapy in the Treatment of Invasive Carcinoma of Larynx and Pharynx: Report from the DAHANCA 2 Study","volume":"16","author":"Overgaard","year":"1989","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0360-3016(90)90105-S","article-title":"Final Report of the Phase i Trial of the Hypoxic Cell Radiosensitizer SR 2508 (Etanidazole) Radiation Therapy Oncology Group 83-03","volume":"18","author":"Coleman","year":"1990","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10637-016-0326-y","article-title":"RRx-001, A Novel Dinitroazetidine Radiosensitizer","volume":"34","author":"Oronsky","year":"2016","journal-title":"Investig. New Drugs"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/cas.13302","article-title":"Biological Effects of Hydrogen Peroxide Administered Intratumorally with or without Irradiation in Murine Tumors","volume":"108","author":"Takaoka","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.2011.35.9315","article-title":"Accelerated Radiotherapy With Carbogen and Nicotinamide for Laryngeal Cancer: Results of a Phase III Randomized Trial","volume":"30","author":"Janssens","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1158\/1078-0432.CCR-17-0038","article-title":"A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients","volume":"23","author":"Yang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/hed.23569","article-title":"Prognostic Value of the Proliferation Marker Ki-67 in Laryngeal Carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide Phase III Randomized Trial","volume":"37","author":"Rademakers","year":"2015","journal-title":"Head Neck"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2008.10.001","article-title":"Carbogen and Nicotinamide in Locally Advanced Bladder Cancer: Early Results of a Phase-III Randomized Trial","volume":"91","author":"Hoskin","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_107","first-page":"7430","article-title":"Combination of Nicotinamide and Hyperthermia to Eliminate Radioresistant Chronically and Acutely Hypoxic Tumor Cells","volume":"50","author":"Horsman","year":"1990","journal-title":"Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2016.386","article-title":"Blood Transfusion during Radical Chemo-Radiotherapy Does Not Reduce Tumour Hypoxia in Squamous Cell Cancer of the Head and Neck","volume":"116","author":"Welsh","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1021\/ja9510774","article-title":"DNA Cleavage by the Antitumor Agent 3-Amino-1,2,4-Benzotriazine 1,4-Dioxide (SR4233):\u2009 Evidence for Involvement of Hydroxyl Radical","volume":"118","author":"Daniels","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2000.18.6.1254","article-title":"Single-Arm, Open-Label Phase II Study of Intravenously Administered Tirapazamine and Radiation Therapy for Glioblastoma Multiforme","volume":"18","author":"Scott","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.bcp.2014.08.003","article-title":"Identification of One-Electron Reductases That Activate Both the Hypoxia Prodrug SN30000 and Diagnostic Probe EF5","volume":"91","author":"Wang","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ijrobp.2017.03.024","article-title":"Clinical Advances of Hypoxia-Activated Prodrugs in Combination with Radiation Therapy","volume":"98","author":"Mistry","year":"2017","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0167-8140(97)00220-X","article-title":"A Randomized Double-Blind Phase III Study of Nimorazole as a Hypoxic Radiosensitizer of Primary Radiotherapy in Supraglottic Larynx and Pharynx Carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85","volume":"46","author":"Overgaard","year":"1998","journal-title":"Radiother. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0070-2153(05)73006-4","article-title":"Histone Deacetylation as a Target for Radiosensitization","volume":"Volume 73","author":"Cerna","year":"2006","journal-title":"Current Topics in Developmental Biology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","article-title":"Postradiation Sensitization of the Histone Deacetylase Inhibitor Valproic Acid","volume":"14","author":"Chinnaiyan","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","article-title":"A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma","volume":"92","author":"Krauze","year":"2015","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","article-title":"Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma","volume":"34","author":"Happold","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/neuonc\/nox161","article-title":"Phase I\/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Results of Alliance N0874\/ABTC 02","volume":"20","author":"Galanis","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Durant, S.T., Zheng, L., Wang, Y., Chen, K., Zhang, L., Zhang, T., Yang, Z., Riches, L., Trinidad, A.G., and Fok, J.H. (2018). The Brain-Penetrant Clinical ATM Inhibitor AZD1390 Radiosensitizes and Improves Survival of Preclinical Brain Tumor Models. Sci. Adv., 4.","DOI":"10.1126\/sciadv.aat1719"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nature01368","article-title":"DNA Damage Activates ATM through Intermolecular Autophosphorylation and Dimer Dissociation","volume":"421","author":"Bakkenist","year":"2003","journal-title":"Nature"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molonc.2014.08.003","article-title":"Abrogation of Radioresistance in Glioblastoma Stem-like Cells by Inhibition of ATM Kinase","volume":"9","author":"Carruthers","year":"2015","journal-title":"Mol. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1158\/1535-7163.MCT-09-0519","article-title":"Improved ATM Kinase Inhibitor KU-60019 Radiosensitizes Glioma Cells, Compromises Insulin, AKT and ERK Prosurvival Signaling, and Inhibits Migration and Invasion","volume":"8","author":"Golding","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1021\/acs.jmedchem.7b01896","article-title":"The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)Propoxy]Pyridin-3-Yl}-3-Methyl-1-(Tetrahydro-2H-Pyran-4-Yl)-1,3-Dihydro-2H-Imidazo[4,5-c]Quinolin-2-One)","volume":"61","author":"Pike","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1021\/jm00374a006","article-title":"Design, Synthesis, and Testing of Potential Antisickling Agents. 4. Structure-Activity Relationships of Benzyloxy and Phenoxy Acids","volume":"27","author":"Abraham","year":"1984","journal-title":"J. Med. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2004.00.1768","article-title":"Phase III Study of Efaproxiral As an Adjunct to Whole-Brain Radiation Therapy for Brain Metastases","volume":"24","author":"Suh","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0360-3016(94)90432-4","article-title":"Direct Measurement of PO2 Distribution and Bioreductive Enzymes in Human Malignant Brain Tumors","volume":"29","author":"Rampling","year":"1994","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0360-3016(94)00494-6","article-title":"In Vivo Radiation Sensitivity of Glioblastoma Multiforme","volume":"32","author":"Taghian","year":"1995","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.2002.01.096","article-title":"Survival of Patients With Newly Diagnosed Glioblastoma Multiforme Treated With RSR13 and Radiotherapy: Results of a Phase II New Approaches to Brain Tumor Therapy CNS Consortium Safety and Efficacy Study","volume":"20","author":"Kleinberg","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrn2175","article-title":"Angiogenesis in Brain Tumours","volume":"8","author":"Jain","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus Radiotherapy\u2013Temozolomide for Newly Diagnosed Glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer Immunoediting: From Immunosurveillance to Tumor Escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12105","article-title":"Cancer Immunoediting: Antigens, Mechanisms, and Implications to Cancer Immunotherapy","volume":"1284","author":"Vesely","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer Immunoediting and Resistance to T Cell-Based Immunotherapy","volume":"16","author":"Teng","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11060-020-03448-1","article-title":"A Review of Glioblastoma Immunotherapy","volume":"151","author":"Medikonda","year":"2021","journal-title":"J. Neurooncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A Decade of Immune-Checkpoint Inhibitors in Cancer Therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and Checkpoint Blockade Immunotherapy: Radiosensitisation and Potential Mechanisms of Synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic Effects of Ablative Radiation on Local Tumor Require CD8+ T Cells: Changing Strategies for Cancer Treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J. Immunol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant Nivolumab Modifies the Tumor Immune Microenvironment in Resectable Glioblastoma","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","article-title":"Immune and Genomic Correlates of Response to Anti-PD-1 Immunotherapy in Glioblastoma","volume":"25","author":"Zhao","year":"2019","journal-title":"Nat. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/jco.2015.33.15_suppl.3010","article-title":"Preliminary Safety and Activity of Nivolumab and Its Combination with Ipilimumab in Recurrent Glioblastoma (GBM): CHECKMATE-143","volume":"33","author":"Sampson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant Anti-PD-1 Immunotherapy Promotes a Survival Benefit with Intratumoral and Systemic Immune Responses in Recurrent Glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of Immunotherapy Resistance: Lessons from Glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current State of Immunotherapy for Glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nbt.2530","article-title":"Heterogeneity of Tumor-Induced Gene Expression Changes in the Human Metabolic Network","volume":"31","author":"Hu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nn.4537","article-title":"Purine Synthesis Promotes Maintenance of Brain Tumor Initiating Cells in Glioma","volume":"20","author":"Wang","year":"2017","journal-title":"Nat. Neurosci."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s41556-019-0363-9","article-title":"IMP Dehydrogenase-2 Drives Aberrant Nucleolar Activity and Promotes Tumorigenesis in Glioblastoma","volume":"21","author":"Kofuji","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1038\/s41467-020-17512-x","article-title":"Purine Metabolism Regulates DNA Repair and Therapy Resistance in Glioblastoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation","volume":"324","author":"Cantley","year":"2009","journal-title":"Science"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1158\/1535-7163.MCT-15-0247","article-title":"Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism","volume":"14","author":"Shen","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Pitroda, S.P., Wakim, B.T., Sood, R.F., Beveridge, M.G., Beckett, M.A., MacDermed, D.M., Weichselbaum, R.R., and Khodarev, N.N. (2009). STAT1-Dependent Expression of Energy Metabolic Pathways Links Tumour Growth and Radioresistance to the Warburg Effect. BMC Med., 7.","DOI":"10.1186\/1741-7015-7-68"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Zoi, V., Galani, V., Tsekeris, P., Kyritsis, A.P., and Alexiou, G.A. (2022). Radiosensitization and Radioprotection by Curcumin in Glioblastoma and Other Cancers. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020312"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Nakamae, I., Morimoto, T., Shima, H., Shionyu, M., Fujiki, H., Yoneda-Kato, N., Yokoyama, T., Kanaya, S., Kakiuchi, K., and Shirai, T. (2019). Curcumin Derivatives Verify the Essentiality of ROS Upregulation in Tumor Suppression. Molecules, 24.","DOI":"10.3390\/molecules24224067"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Zeng, Y., Du, Q., Zhang, Z., Ma, J., Han, L., Wang, Y., Yang, L., Tao, N., and Qin, Z. (2020). Curcumin Promotes Cancer-Associated Fibroblasts Apoptosis via ROS-Mediated Endoplasmic Reticulum Stress. Arch. Biochem. Biophys., 694.","DOI":"10.1016\/j.abb.2020.108613"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Zoi, V., Galani, V., Vartholomatos, E., Zacharopoulou, N., Tsoumeleka, E., Gkizas, G., Bozios, G., Tsekeris, P., Chousidis, I., and Leonardos, I. (2021). Curcumin and Radiotherapy Exert Synergistic Anti-Glioma Effect In Vitro. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111562"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"9211","DOI":"10.1158\/0008-5472.CAN-06-2181","article-title":"Inhibition of Hsp90 Compromises the DNA Damage Response to Radiation","volume":"66","author":"Dote","year":"2006","journal-title":"Cancer Res."},{"key":"ref_161","first-page":"8984","article-title":"Geldanamycin and 17-Allylamino-17-Demethoxygeldanamycin Potentiate the in Vitro and in Vivo Radiation Response of Cervical Tumor Cells via the Heat Shock Protein 90-Mediated Intracellular Signaling and Cytotoxicity","volume":"63","author":"Bisht","year":"2003","journal-title":"Cancer Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/09553000310001626135","article-title":"Geldanamycin, an Inhibitor of Hsp90, Sensitizes Human Tumour Cells to Radiation","volume":"79","author":"Machida","year":"2003","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3892\/ol.2022.13222","article-title":"Preferential Radiosensitization to Glioblastoma Cancer Stem Cell-like Cells by a Hsp90 Inhibitor, N-vinylpyrrolidone-AUY922","volume":"23","author":"Tani","year":"2022","journal-title":"Oncol. Lett."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Miles, X., Vandevoorde, C., Hunter, A., and Bolcaen, J. (2021). MDM2\/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.703442"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41467-021-21145-z","article-title":"P53 Dynamics Vary between Tissues and Are Linked with Radiation Sensitivity","volume":"12","author":"Iwamoto","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1158\/0008-5472.CAN-18-0440","article-title":"The MDM2\/MDMX-P53 Antagonist PM2 Radiosensitizes Wild-Type P53 Tumors","volume":"78","author":"Spiegelberg","year":"2018","journal-title":"Cancer Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1078-0432.CCR-15-1015","article-title":"Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-Type Glioblastomas","volume":"22","author":"Verreault","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"O\u2019Rourke, D.M., Nasrallah, M.P., Desai, A., Melenhorst, J.J., Mansfield, K., Morrissette, J.J., Martinez-Lage, M., Brem, S., Maloney, E., and Shen, A. (2017). A Single Dose of Peripherally Infused EGFRvIII-Directed CAR T Cells Mediates Antigen Loss and Induces Adaptive Resistance in Patients with Recurrent Glioblastoma. Sci. Transl. Med., 9.","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.21037\/tlcr.2017.03.07","article-title":"Preclinical Rationale for Combining Radiation Therapy and Immunotherapy beyond Checkpoint Inhibitors (i.e., CART)","volume":"6","author":"Flynn","year":"2007","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/neuonc\/nox116","article-title":"CD70, a Novel Target of CAR T-Cell Therapy for Gliomas","volume":"20","author":"Jin","year":"2018","journal-title":"Neuro-Oncology"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1763\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:55:42Z","timestamp":1760140542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":171,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071763"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071763","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]}}}